Immunotherapy has proven effective in metastatic renal cell carcinoma (RCC). The current standard of treatment in localized RCC is partial or complete nephrectomy. However, after surgery, there is a high recurrence rate and survival rates ranging from 53% to 85% depending on the stage of disease at presentation. Given clinical response to immunotherapies in metastatic RCC, these therapies are being tested as monotherapy and in combination with vascular endothelial growth factor receptor tyrosine kinase inhibitors in the (neo)adjuvant setting. Here we describe the current landscape of these treatments in localized RCC.

中文翻译：

---

围手术期免疫治疗在局限性肾细胞癌中的作用。

免疫疗法已被证明对转移性肾细胞癌（RCC）有效。目前局限性肾细胞癌的治疗标准是部分或完全肾切除术。然而，手术后复发率很高，生存率根据疾病的分期从 53% 到 85% 不等。鉴于转移性肾细胞癌免疫疗法的临床反应，这些疗法正在作为单一疗法以及在（新）辅助治疗中与血管内皮生长因子受体酪氨酸激酶抑制剂联合进行测试。在这里，我们描述了这些治疗方法在局部肾细胞癌中的现状。